Low testosterone is associated with disability in men with multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 12, 2014, Pages 1584-1592

  Bove, R ^a,b   Musallam, A ^a   Healy, B C ^a,b,c   Raghavan, K ^b   Glanz, B I ^a,b   Bakshi, R ^a,b   Weiner, H ^a,b   De Jager, P L ^a,b   Miller, K K ^b,c   Chitnis, T ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Body mass index; cognition; cognitive impairment; disability; hormones; hypogonadism; leptin; multiple sclerosis; testosterone

Indexed keywords

25 HYDROXYVITAMIN D; ESTRADIOL; LEPTIN; LUTEINIZING HORMONE; TESTOSTERONE; BETA1A INTERFERON; CALCIFEDIOL; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; SEX HORMONE BINDING GLOBULIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT TOOL; CLINICAL STUDY; COGNITION; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEMYELINATING DISEASE; DISABILITY; DISEASE ASSOCIATION; DISEASE DURATION; ESTRADIOL BLOOD LEVEL; EXPANDED DISABILITY STATUS SCALE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PREVALENCE; SYMBOL DIGIT MODALITIES TEST; TESTOSTERONE BLOOD LEVEL; AGE DISTRIBUTION; COGNITION ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HYPOGONADISM; LUTEINIZING HORMONE BLOOD LEVEL; ONSET AGE; ADOLESCENT; BLOOD; DISABLED PERSON; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TESTOSTERONE; YOUNG ADULT;

EID: 84907853173     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514527864     Document Type: Article

References (39)

1. Bove R, Chitnis T. Sexual disparities in the incidence and course of MS. Clin Immunol. 2013 ; 149 (2). 201-210
2. Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol. 2004 ; 251: 1208-1214
3. Shawaryn MA, Schiaffino KM, LaRocca NG, et al. Determinants of health-related quality of life in multiple sderosis: The role of illness intrusiveness. Mult Scler. 2002 ; 8: 310-318
4. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res. 2009 ; 175: 239-251
5. Anawalt BD, Merriam GR. Neuroendocrine aging in men. Andropause and somatopause. Endocrinol Metab Clin North Am. 2001 ; 30: 647-669
6. Safarinejad MR. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis. J Neuroendocrinol. 2008 ; 20: 1368-1375
7. Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry. 2005 ; 76: 272-275
8. Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain. 1997 ; 120: 1067-1076
9. Bove RM. Autoimmune diseases and reproductive aging. Clin Immunol. 2013 ; 149: 251-264
10. Munger KL, Ascherio A. Prevention and treatment of MS: Studying the effects of vitamin D. Mult Scler. 2011 ; 17: 1405-1411
11. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009 ; 73: 1543-1550
12. Matarese G, Carrieri PB, Montella S, et al. Leptin as a metabolic link to multiple sclerosis. Nat Rev Neurol. 2010 ; 6: 455-461
13. Gauthier SA, Glanz BI, Mandel M, et al. A model for the comprehensive investigation of a chronic autoimmune disease: The multiple sclerosis CLIMB study. Autoimmun Rev. 2006 ; 5: 532-536
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846
15. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men, generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011 ; 96: 2430-2439
16. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999 ; 84: 3666-3672
17. Kurtzke J. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
18. Amato MP, Portaccio E, Goretti B, et al. Relevance of cognitive deterioration in early relapsing-remitting MS: A 3-year follow-up study. Mult Scler. 2010 ; 16: 1474-1482
19. Glanz BI, Healy BC, Hviid LE, et al. Cognitive deterioration in patients with early multiple sclerosis: A 5-year study. J Neurol Neurosurg Psychiatry. 2012 ; 83: 38-43
20. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Am Med Ass. 2006 ; 296: 2832-2838
21. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986 ; 73: 13-22
22. Bhasin S, Basaria S. Diagnosis and treatment of hypogonadism in men. Best Pract Res Clin Endocrinol Metab. 2011 ; 25: 251-270
23. Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists' medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract. 2002 ; 8: 440-456
24. Bobjer J, Naumovska M, Giwercman YL, et al. High prevalence of androgen deficiency and abnormal lipid profile in infertile men with non-obstructive azoospermia. Int J Androl. 2012 ; 35: 688-694
25. Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011 ; 26: 184-190
26. Nimptsch K, Platz EA, Willett WC, et al. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf). 2012 ; 77: 106-112
27. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: The European Male Ageing Study. Eur J Endocrinol. 2012 ; 166: 77-85
28. Michalakis K, Mintziori G, Kaprara A, et al. The complex interaction between obesity, metabolic syndrome and reproductive axis: A narrative review. Metabolism. 2013 ; 62: 457-478
29. Neale SM, Hocking R, Biswas M, et al. Adult testosterone and calculated free testosterone reference ranges by tandem mass spectrometry. Ann Clin Biochem. 2013 ; 50: 159-161
30. Yeap BB, Alfonso H, Chubb SA, et al. Reference ranges and determinants of testosterone, dihydrotestosterone and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab. 2012 ; 97: 4030-4039
31. Marrie RA, Yu N, Wei Y, et al. High rates of physician services utilization at least five years before multiple sclerosis diagnosis. Mult Scler. 2013 ; 19 (8). 1113-1119
32. Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: A review. Maturitas. 2011 ; 69: 322-337
33. Sicotte NL, Kern KC, Giesser BS, et al. Regional hippocampal atrophy in multiple sclerosis. Brain. 2008 ; 131: 1134-1141
34. Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: A pilot study. Arch Neurol. 2007 ; 64: 683-688
35. Gold SM, Chalifoux S, Giesser BS, et al. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflamm. 2008 ; 5: 32
36. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest. 1999 ; 22: 110-116
37. Mowry EM. Vitamin D: Evidence for its role as a prognostic factor in multiple sclerosis. J Neurol Sci. 2011 ; 311: 19-22
38. Correale J, Ysrraelit MC, Gaitan MI. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol. 2010 ; 185: 4948-4958
39. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features in childhood and juvenile MS: Two-year follow-up. Neurology. 2010 ; 75: 1134-1140